1 / 5

Hemophilia Market Size, Share, Growth, Research and Forecast 2020-2026

The global hemophilia market is anticipated to grow with a significant CAGR of 6% during the forecast period. The hemophilia market growth is owing to the increasing demand for the prophylactic treatment of hemophilia. In addition to this, the increasing engagement of healthcare professionals, hemophilia treatment centers, as well as hemophilia societies to improve the care of hemophilia patients and their quality of life is also expected to drive the hemophilia market shares.

shriram01
Download Presentation

Hemophilia Market Size, Share, Growth, Research and Forecast 2020-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Orion Market Research Hemophilia Market Size, Share, Growth, Research and Forecast 2020-2026 Request a free sample of our report on Hemophilia Market: https://www.omrglobal.com/request- sample/hemophilia-market ------------------------------------------------------------------------------------ Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +1 646-755-7667, +91 7803040404

  2. The global hemophilia market is anticipated to grow with a significant CAGR of 6% during the forecast period. The hemophilia market growth is owing to the increasing demand for the prophylactic treatment of hemophilia. In addition to this, the increasing engagement of healthcare professionals, hemophilia treatment centers, as well as hemophilia societies to improve the care of hemophilia patients and their quality of life is also expected to drive the hemophilia market shares. Moreover, the continuous evolving treatment of hemophilia in recent years is also anticipated to propel the growth of the hemophilia market. A full report of Hemophilia Market is available at: https://www.omrglobal.com/industry- reports/hemophilia-market In general, the treatment of monogenetic bleeding disorders that is hemophilia A and B was done with the systemic protein replacement therapy. However, in recent years, a variety of diverse molecular medicines, ranging from antibody to gene to RNA therapy are transforming the treatment of hemophilia. Moreover, the traditional replacement therapy used in the treatment of hemophilia required intravenous infusions of the factors for two to three times a week. While the new therapies in the market with extended half-life products are expected to reduce the frequency of injections. Additionally, multiple gene-editing techniques are under clinical or preclinical investigation for the treatment of hemophilia. Therefore, these new therapies and approaches that are being tested or launched are anticipated to considerably drive the size of the hemophilia industry during the forecast period. To learn more about this report request a free sample copy @ https://www.omrglobal.com/request- sample/hemophilia-market In addition to this, several potential drugs can be used for the treatment of hemophilia are in their trials phase. These potential drugs are anticipated to provide new opportunities for the growth of the hemophilia market upon their market launch. For instance, Fitusiran an RNA-interference drug is in its Phase III trials. It is intended to be once a month injection that can both inhibits antithrombins and promotes the production of thrombin. Fitusiran can be used in both hemophilia A as well as hemophilia B treatment. Moreover, in January 2020 Sangamo Therapeutics has handed over the development of SB- 525, (a gene therapy for hemophilia A), to Pfizer Inc. The company will now advance the therapy into Phase 3 clinical trials.

  3. Global Hemophilia Market- Segmentation By Type Hemophilia A Hemophilia B Others By Therapy Replacement Therapy Gene Therapy Others By Product Type Recombinant Coagulation Factor Concentrates Plasma-derived Coagulation Factor Concentrates Others For more customized data, request for report customization @ https://www.omrglobal.com/report- customization/hemophilia-market Global Hemophilia Market- Segment by Region North America United States Canada Europe Germany United Kingdom France Spain Italy Rest of Europe

  4. Asia-Pacific China Japan India Rest of Asia-Pacific Rest of the World Middle East & Africa Latin America Company Profiles Alnylam Pharmaceuticals, Inc Baxter International, Inc. Bayer AG BioMarin Pharmaceutical Inc. Biotest AG Catalyst Biosciences Inc. CSLLtd. Emergent BioSolutions Inc. F. Hoffmann-La Roche Ltd. GC Pharma (Green Cross Corp.) Genentech Inc. (HEMLIBRA) Grifols, S.A. Kedrion S.p.A Medexus Pharmaceuticals, Inc. Nektar Therapeutics Novo Nordisk A/S Octapharma AG Pfizer, Inc. Sanofi SA Spark Therapeutics, Inc. Swedish Orphan Biovitrum AB Takeda Pharmaceutical Company Ltd.

  5. About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research- based services. For More Information, Visit Orion Market Research Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 7803-040-404

More Related